Yesterday was the National Future Career Day in Switzerland (Zukunftstag) and we welcomed six enthusiastic future potential scientists to the Bright Peak offices and labs. 👨🔬 👩🔬 👨🔬 👩🔬 👨🔬 👩🔬 We started with a boardroom breakfast meeting and moved quickly into the labs to share the work with our peptide chemists. The day ended with the development of an interesting plan to sublease the new offices by our entrepreneurial guests. Thanks to all, young and old(er), that made the day such a great success. We hope it will inspire the next generation of scientists and biotech founders.
Info
Bright Peak are developing a portfolio of first-in-class and best-in-class cytokines with optimized biological properties for the treatment of cancer and autoimmune diseases. Through a variety of proprietary technology platforms, Bright Peak is uniquely abled to conjugate its cytokines as payloads to antibodies, creating bespoke, novel and proprietary “Bright Peak Immunocytokines”, and to other cytokines as “duokines”. The Bright Peak Immunocytokines allow tissue- and cell-specific targeting of the cytokine payload with the added potential for significantly enhanced efficacy. One of the many advantages of our approach is its "off-the-shelf" feature. Using a pioneering site-specific ADC-like chemical conjugation technology, any therapeutic antibody at any stage of development can be conjugated with Bright Peak’s cytokine payloads of choice, eliminating the current complexities of antibody engineering and cell line development. Bright Peak’s team works with a passion for innovation and bold science. We are an international research-driven organization dedicated to discovering and developing cutting edge therapies that will make a difference in the lives of patients. We aim to create a vibrant and international corporate culture and are currently hiring in our Basel, Switzerland and Southern California locations.
- Website
-
https://www.brightpeaktx.com/
Externer Link zu Bright Peak Therapeutics
- Branche
- Biotechnologieforschung
- Größe
- 51–200 Beschäftigte
- Hauptsitz
- Basel
- Art
- Privatunternehmen
- Gegründet
- 2017
Orte
-
Primär
Wegbeschreibung
Klybeckstrasse 191
WKL-136.4.93
Basel, 4057, CH
-
Wegbeschreibung
2010 Jimmy Durante Blvd
Suite 150
Del Mar, California 92014, US
Beschäftigte von Bright Peak Therapeutics
Updates
-
Bright Peak's CSO Bertolt Kreft presented the preclinical data supporting our journey to phase 1 for BPT567 on day one of the Festival of Biologics. Plenty of other Bright Peak colleagues are participating in the Festival as well, which is a great chance to hear from our peers and to meet our suppliers and collaborators.
-
-
We're #hiring a new Senior Director of Biology in Allschwil, Basel-Country. Apply today or share this post with your network.
-
We're #hiring a new Senior Director of Biology. If you are an experienced drug discovery leader looking for a new challenge with novel #biologics, then we may have the position you're looking for. Apply today or share this post with your network.
-
Bright Peak took advantage of a break in the rain for our summer party in the woods above Basel last week. With the help of families, friends, Escola de Samba GmbH & Co. KG and Eiche Metzgerei we had a noisy evening of Samba percussion, good food and relaxation. This was fun; thanks to everyone for joining in!
-
-
Bright Peak is looking for a talented assay specialist to help build our pipeline of immunoconjugates. If you're passionate about drug discovery and this fits your experience, apply on our website - we look forward to hearing from you. https://lnkd.in/duWt8bvc
-
Our CEO Fred Wiklund was interviewed in the most recent edition of San Diego Business Journal to discuss Bright Peak’s recent $90M financing. You can acess the full article below.
-
Bright Peak Therapeutics hat dies direkt geteilt
Thanks NYSE for having the Bright Peak Therapeutics “Trading Floor Takeover” announcing and celebrating our recent $90M Series C financing.
-
-
Our Chief Technology Officer and Founder Vijaya R. Pattabiraman will be speaking this month at the Johnson & Johnson Therapeutic Peptide Symposium, as an invited guest of J&J Innovative Medicine Belgium, about Bright Peak Therapeutics' unique capabilities to make designer biotherapeutics. Find out more at the J&J website here: https://rndsymposium.be/
-
-
Bright Peak Therapeutics hat dies direkt geteilt
Thanks for sharing the news from Bright Peak!
Bright Peak Therapeutics bags $90 million Series C to develop cancer immunotherapies
biopharma-reporter.com